Diagnostic Imaging Services Market (By Modality: X-ray, Nuclear Medicine Scans, MRI Scans, CT scans, Ultrasounds; By End Use: Hospitals and Diagnostic Imaging Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Diagnostic Imaging Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Diagnostic Imaging Services Market, by Modality Type, 2023-2032
8.1.1. X-ray
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Nuclear Medicine Scans
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. MRI Scans
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. CT Scans
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Ultrasound
8.1.5.1. Market Revenue and Forecast (2020-2032)
9.1. Diagnostic Imaging Services Market, by End Use, 2023-2032
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Diagnostic Imaging Centers
9.1.2.1. Market Revenue and Forecast (2020-2032)
10.1. North America
10.1.1. Market Revenue and Forecast, by Modality (2020-2032)
10.1.2. Market Revenue and Forecast, by End Use (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Modality (2020-2032)
10.1.3.2. Market Revenue and Forecast, by End Use (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Modality (2020-2032)
10.1.4.2. Market Revenue and Forecast, by End Use (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Modality (2020-2032)
10.2.2. Market Revenue and Forecast, by End Use (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Modality (2020-2032)
10.2.3.2. Market Revenue and Forecast, by End Use (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Modality (2020-2032)
10.2.4.2. Market Revenue and Forecast, by End Use (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Modality (2020-2032)
10.2.5.2. Market Revenue and Forecast, by End Use (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Modality (2020-2032)
10.2.6.2. Market Revenue and Forecast, by End Use (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Modality (2020-2032)
10.3.2. Market Revenue and Forecast, by End Use (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Modality (2020-2032)
10.3.3.2. Market Revenue and Forecast, by End Use (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Modality (2020-2032)
10.3.4.2. Market Revenue and Forecast, by End Use (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Modality (2020-2032)
10.3.5.2. Market Revenue and Forecast, by End Use (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Modality (2020-2032)
10.3.6.2. Market Revenue and Forecast, by End Use (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Modality (2020-2032)
10.4.2. Market Revenue and Forecast, by End Use (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Modality (2020-2032)
10.4.3.2. Market Revenue and Forecast, by End Use (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Modality (2020-2032)
10.4.4.2. Market Revenue and Forecast, by End Use (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Modality (2020-2032)
10.4.5.2. Market Revenue and Forecast, by End Use (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Modality (2020-2032)
10.4.6.2. Market Revenue and Forecast, by End Use (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Modality (2020-2032)
10.5.2. Market Revenue and Forecast, by End Use (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Modality (2020-2032)
10.5.3.2. Market Revenue and Forecast, by End Use (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Modality (2020-2032)
10.5.4.2. Market Revenue and Forecast, by End Use (2020-2032)
11.1. Global Diagnostics
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. RadNet, Inc
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Alliance Medical
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Center for Diagnostic Imaging, Inc
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Medica Group
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Novant Health
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Concord Medical Services Holdings Limited
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. InHealth Group
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Sonic Healthcare
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Healthcare Imaging Services Pty Ltd.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client